2nd Quarter - Report

WILLIAMS AND JENSEN, PLLC for PHRMA

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

National Defense Authorization Act, policies related to pharmaceutical reimbursement and access.

LobbyistCovered position, as disclosed
CHERYL LYNN JAEGER Shrd Employee, Ofc of the Speaker & Ofc of VA 7; Sr Policy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr LA to Rep Cox

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Drug Pricing Program. CMMI Medicare Part B Demonstration; Right to Try; H.R. 1231, RACE for Children Act. Independent Payment Advisory Board. H.R. 1625, Consolidated Appropriations Act of FY 2019. Legislation to address opioid addiction and treatment, including H.R. 6 SUPPORT for Patients and Communities Act.

LobbyistCovered position, as disclosed
CHRISTOPHER W HATCHER New Sc. C, Treasury; LD, Rep Mcinnis
SUSAN HIRSCHMANN —
MATTHEW B HOEKSTRA —
CHERYL LYNN JAEGER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1231 (115th), H.R. 6 (115th), H.R. 1625 (115th)

Budget/Appropriations BUD

Issues related to pharmaceutical development. Policies impacting Medicare Part D, H.R. 1625, Consolidated Appropriations Act. H.R. 1892, the Bipartisan Budget Act of 2018

LobbyistCovered position, as disclosed
SUSAN HIRSCHMANN COS, Rep Van Hilleary and Majority Whip
CHERYL LYNN JAEGER Shrd employee, Ofc of the Speaker & Ofc of VA 7; Sr Policy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Republican Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Roy Blunt; Prof Staff House Committee E&C; SR LA Rep Cox.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1625 (115th), H.R. 1892 (115th)

Medicare/Medicaid MMM

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Medicare Part D. Importation. 340B Drug Pricing Program. CMMI Medicare Part B Demonstration.

LobbyistCovered position, as disclosed
SUSAN HIRSCHMANN —
MATTHEW B HOEKSTRA —
CHERYL LYNN JAEGER —
KARINA LYNCH —
ERIN BOOK MULLEN —
GEORGE OLSEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.